Literature DB >> 20668427

Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.

Bradley A Ford1, Charles S Eby, Mitchell G Scott, Daniel W Coyne.   

Abstract

An accurate assessment of iron status in dialysis patients is important because both anemia and overtreatment with erythropoiesis-stimulating agents are associated with poor clinical outcomes. We have previously shown that both analytical and intra-individual (biological) variability in serum ferritin limits its utility as a proxy for iron stores in patients in this setting. As hepcidin is a direct regulator of iron status, its measurement might be useful for monitoring patients with iron dysregulation. We assessed short-term intra-individual variation of serum hepcidin in 28 patients with stable chronic kidney disease on hemodialysis. The intra-individual variability for serum hepcidin ranged from 9-79% during an initial 2-week to 12-85% over a 6-week period. The concentration of serum hepcidin was significantly correlated with serum C-reactive protein levels over the 6-week study period. Hence, significant intra-individual variability of hepcidin is likely dependent on short-term fluctuations in the inflammatory state. Thus, our results suggest that short-term measurement of serum hepcidin should not be used to guide clinical decisions regarding management of iron status in chronic hemodialysis patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668427     DOI: 10.1038/ki.2010.254

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  31 in total

1.  Serum hepcidin-25 and response to intravenous iron in patients with non-dialysis chronic kidney disease.

Authors:  Sourabh Chand; Douglas G Ward; Zhi-Yan Valerie Ng; James Hodson; Heidi Kirby; Patricia Steele; Irina Rooplal; Ferly Bantugon; Tariq Iqbal; Chris Tselepis; Mark T Drayson; Alison Whitelegg; Marie Chowrimootoo; Richard Borrows
Journal:  J Nephrol       Date:  2014-04-01       Impact factor: 3.902

2.  Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.

Authors:  Meredith A Atkinson; Stephen P Juraschek; Michael S Bertenthal; Barbara Detrick; Susan L Furth; Edgar R Miller
Journal:  Pediatr Nephrol       Date:  2016-12-24       Impact factor: 3.714

3.  Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.

Authors:  Meredith A Atkinson; Ji Young Kim; Cindy N Roy; Bradley A Warady; Colin T White; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2014-11-08       Impact factor: 3.714

Review 4.  Markers of iron status in chronic kidney disease.

Authors:  Adam E Gaweda
Journal:  Hemodial Int       Date:  2017-03-22       Impact factor: 1.812

5.  A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?

Authors:  Nicola Tessitore; Albino Poli; Valeria Bedogna; Luca Corazza; Natascia Campostrini; Mauro Atti; Luisa Sereni; Annalisa Castagna; Domenico Girelli; Giuseppina Pessolano; Antonio Lupo
Journal:  J Nephrol       Date:  2017-03-28       Impact factor: 3.902

6.  Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.

Authors:  Lavinia Oltiţa Brătescu; Liliana Bârsan; Liliana Gârneaţă; Ana Stanciu; Mariana Lipan; Simona Hildegard Stancu; Gabriel Mircescu
Journal:  Int Urol Nephrol       Date:  2014-03-29       Impact factor: 2.370

7.  Serum copper and ferroportin in monocytes of hemodialysis patients are both decreased but unassociated.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Georgios Filippidis; Spyridon Golfinopoulos; Aginor Spanoulis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2014-05-08       Impact factor: 2.370

Review 8.  The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.

Authors:  Kimberly Zumbrennen-Bullough; Jodie L Babitt
Journal:  Nephrol Dial Transplant       Date:  2013-11-13       Impact factor: 5.992

9.  Can Serum Gdf-15 be Associated with Functional Iron Deficiency in Hemodialysis Patients?

Authors:  Hakki Yilmaz; Muzaffer Cakmak; Tahir Darcin; Osman Inan; Mukadder Ayse Bilgic; Nuket Bavbek; Ali Akcay
Journal:  Indian J Hematol Blood Transfus       Date:  2015-05-27       Impact factor: 0.900

10.  Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Remoundou; Georgios Filippidis; Georgia Antoniadi; Niki Oustampasidou; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2013-07-17       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.